Tsai Steve, Klapholz Marc
University of Medicine and Dentistry of New Jersey--New Jersey Medical School, 185 South Orange Avenue, MSB I-536, Newark, NJ, 07103 USA.
Curr Heart Fail Rep. 2007 Jun;4(2):110-6. doi: 10.1007/s11897-007-0009-2.
beta-blockade has a therapeutic role across the continuum of patients with heart failure (HF), with a demonstrated mortality benefit in stage II and III HF. Concerns regarding initiation and uptitration linger as patients with resting bradycardia, pulmonary, or vascular disease are often unnecessarily excluded from receiving therapy. We will review the risk data on beta-blockade and offer therapeutic strategies to help overcome residual barriers to the initiation and uptitration of this important therapy in patients with HF.
β受体阻滞剂在心力衰竭(HF)患者的整个病程中都具有治疗作用,已证明其在II期和III期HF患者中有降低死亡率的益处。由于静息性心动过缓、肺部或血管疾病患者常常被不必要地排除在接受治疗之外,因此对于β受体阻滞剂的起始用药和剂量滴定仍存在担忧。我们将回顾β受体阻滞剂的风险数据,并提供治疗策略,以帮助克服在HF患者中启动和滴定这一重要治疗方法时存在的残余障碍。